{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:12:15Z","timestamp":1788671535765,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M781933"],"award-info":[{"award-number":["2025M781933"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2022YFC280480"],"award-info":[{"award-number":["2022YFC280480"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2022YFC2804800"],"award-info":[{"award-number":["2022YFC2804800"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2020YFA0803202"],"award-info":[{"award-number":["2020YFA0803202"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["23ZR1412100"],"award-info":[{"award-number":["23ZR1412100"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["18ZR1404500"],"award-info":[{"award-number":["18ZR1404500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["25ZR1402089"],"award-info":[{"award-number":["25ZR1402089"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072693"],"award-info":[{"award-number":["82072693"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172884"],"award-info":[{"award-number":["82172884"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503291"],"award-info":[{"award-number":["82503291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573937"],"award-info":[{"award-number":["82573937"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472954"],"award-info":[{"award-number":["82472954"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pan.2026.07.013","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:38:03Z","timestamp":1784936283000},"page":"896-907","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids"],"prefix":"10.1016","volume":"26","author":[{"given":"Xu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4807-9614","authenticated-orcid":false,"given":"He","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pan.2026.07.013_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.pan.2026.07.013_bib2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"issue":"18","key":"10.1016\/j.pan.2026.07.013_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pan.2026.07.013_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.pan.2026.07.013_bib5","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pan.2026.07.013_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","article-title":"Towards precision oncology with patient-derived xenografts","volume":"19","author":"Zanella","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.pan.2026.07.013_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.pan.2026.07.013_bib8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","article-title":"Modeling development and disease with organoids","volume":"165","author":"Clevers","year":"2016","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.pan.2026.07.013_bib9","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nm.3973","article-title":"Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids","volume":"21","author":"Huang","year":"2015","journal-title":"Nat Med"},{"issue":"52","key":"10.1016\/j.pan.2026.07.013_bib10","doi-asserted-by":"crossref","first-page":"26580","DOI":"10.1073\/pnas.1911273116","article-title":"Pancreatic cancer organoids recapitulate disease and allow personalized drug screening","volume":"116","author":"Driehuis","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pan.2026.07.013_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12935-021-02044-1","article-title":"A pancreas tumor derived organoid study: from drug screen to precision medicine","volume":"21","author":"Yao","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"10.1016\/j.pan.2026.07.013_bib12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pan.2026.07.013_bib13","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/nprot.2016.097","article-title":"Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation","volume":"11","author":"Broutier","year":"2016","journal-title":"Nat Protoc"},{"issue":"9","key":"10.1016\/j.pan.2026.07.013_bib14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.pan.2026.07.013_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.pan.2026.07.013_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fcell.2020.00166","article-title":"Modeling cell communication in cancer with organoids: making the complex simple","volume":"8","author":"Fiorini","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.pan.2026.07.013_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.pan.2026.07.013_bib18","article-title":"Toward reproducible tumor organoid culture: focusing on primary liver cancer","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.pan.2026.07.013_bib19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","article-title":"Breakthroughs and challenges of organoid models for assessing cancer immunotherapy","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.pan.2026.07.013_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/boc.202100003","article-title":"A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX","volume":"114","author":"Hadj Bachir","year":"2022","journal-title":"Biol Cell"},{"issue":"15","key":"10.1016\/j.pan.2026.07.013_bib21","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/1078-0432.CCR-21-4165","article-title":"Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response","volume":"28","author":"Sepp\u00e4l\u00e4","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.pan.2026.07.013_bib22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment","volume":"57","author":"de Man","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"3A","key":"10.1016\/j.pan.2026.07.013_bib23","first-page":"2067","article-title":"In vitro activation of irinotecan to SN-38 by human liver and intestine","volume":"19","author":"Ahmed","year":"1999","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.pan.2026.07.013_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.pan.2026.07.013_bib25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"CD39+ HBV surface protein-targeted CAR-T cells exhibit potent anti-HCC activity","volume":"29","author":"Zou","year":"2021","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.pan.2026.07.013_bib26","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.21037\/jtd.2018.04.91","article-title":"EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma","volume":"10","author":"Shi","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.pan.2026.07.013_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102111","article-title":"EphA2-specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer","volume":"50","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"issue":"3\u20134","key":"10.1016\/j.pan.2026.07.013_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric antigen receptor-modified T cells targeting EphA2 for paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.pan.2026.07.013_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/1568009053765780","article-title":"EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics","volume":"5","author":"Ireton","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.pan.2026.07.013_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/0008-5472.CAN-15-0717","article-title":"EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer","volume":"76","author":"Amato","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.pan.2026.07.013_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1535-7163.MCT-18-0539","article-title":"EPHA2 is a predictive biomarker of resistance and a potential therapeutic target in colorectal cancer","volume":"18","author":"Martini","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.pan.2026.07.013_bib32","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbrc.2004.06.054","article-title":"Ligation of EphA2 inhibits pancreatic adenocarcinoma cellular invasiveness","volume":"320","author":"Duxbury","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.pan.2026.07.013_bib33","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","article-title":"Effects of dasatinib on EphA2 receptor tyrosine kinase activity in pancreatic cancer","volume":"99","author":"Chang","year":"2008","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1016\/j.pan.2026.07.013_bib34","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1158\/1078-0432.CCR-19-1398","article-title":"Identification of resistance pathways using organoid models of pancreatic cancer","volume":"25","author":"Ponz-Sarvise","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6747","key":"10.1016\/j.pan.2026.07.013_bib35","doi-asserted-by":"crossref","first-page":"eadk3487","DOI":"10.1126\/science.adk3487","article-title":"Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition","volume":"388","author":"Ely","year":"2025","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pan.2026.07.013_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer serve as a personal evaluation model for CAR-T cells","volume":"10","author":"Yu","year":"2021","journal-title":"Clin Transl Immunol"},{"issue":"5","key":"10.1016\/j.pan.2026.07.013_bib37","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"Potent anti-HCC activity of CD39-targeted CAR-T cells","volume":"29","author":"Zou","year":"2021","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.pan.2026.07.013_bib38","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","article-title":"Generation and biobanking of patient-derived glioblastoma organoids and application in CAR T cell testing","volume":"15","author":"Jacob","year":"2020","journal-title":"Nat Protoc"}],"updated-by":[{"DOI":"10.1016\/j.pan.2026.09.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000}}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032600253X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032600253X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:21:30Z","timestamp":1788668490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S142439032600253X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S142439032600253X"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2026.07.013","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative evaluation of chemotherapy and CAR-T cell therapy in genetically engineered self-sustaining primary pancreatic cancer organoids","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2026.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}